wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1181.
1 2 3 4 5 ... 24 Next »

Medicine/Pharmacology - Business/Economics
21.08.2017
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission   KAF156 is first compound fro
Life Sciences - Medicine/Pharmacology
21.08.2017
Fundamentals of life: How centrosomes direct early embryos
Fundamentals of life: How centrosomes direct early embryos
Summer Series: Sarah Herrman is visiting Pierre GŲnczy's lab at EPFL from the University of California, Santa Cruz.
Medicine/Pharmacology - Life Sciences
17.08.2017
Hemorrhagic Fevers: Countering Inflammation to Prevent Circulatory Failure
Hemorrhagic fevers are severe viral diseases that are often fatal. Researchers from the University of Basel have now identified messenger substances of the immune system, which in infected mice lead to the development of shock. These results, published in the scientific journal Cell Host & Microbe, open up new possibilities for the development of life-saving therapies.
Medicine/Pharmacology
14.08.2017
Drug Approval: New Country Comparison Shows Great Savings Potential
The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. This reports a study of the European Center of Pharmaceutical Medicine at the University of Basel.
Medicine/Pharmacology - Microtechnics/Electroengineering
10.08.2017
An expert in tiny medical helpers
An expert in tiny medical helpers
Simone SchŁrle likes to get to the bottom of things. Since August, the microand nanotechnology expert has been working as Assistant Professor of Responsive Biomedical Systems at ETH Zurich to develop tiny machines for medical applications in the human body.
Medicine/Pharmacology - Physics/Materials Science
03.08.2017
Testing the Limits for the Patients’ Benefit
Radiation therapy using protons is a success story at the Paul Scherrer Institute PSI. For several decades now, doctors have been administering a gentle form of radiation treatment to patients with ocular tumours or those located deep inside the body.
Medicine/Pharmacology - Life Sciences
27.07.2017
Malaria Already Endemic in the Mediterranean by the Roman Period
Even today, Malaria is one of the greatest medical challenges worldwide, killing hundreds of thousands of people every year. In the past, people have adapted to the threat of malaria in various ways. These methods range from interventions in the environment like draining swamps, to genetic adaptations in the human body.
Medicine/Pharmacology - Business/Economics
25.07.2017
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%,
Medicine/Pharmacology
24.07.2017
Deforming virtual reality, on purpose
Deforming virtual reality, on purpose
Summer series - Students projects.†For his Master's project in computer science, Sidney Bovet developed a system that distorts - or more specifically, amplifies - an avatar's movements relative to the user's.
Medicine/Pharmacology - Life Sciences
21.07.2017
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positi
Medicine/Pharmacology - Life Sciences
21.07.2017
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation ba
Life Sciences - Medicine/Pharmacology
20.07.2017
Innate Reaction of Hematopoietic Stem Cells to Severe Infections
If severe infections result, the body must form more white blood cells to fight off infectious agents. Hematopoietic stem cells in the bone marrow are responsible for their production. These cells, which renew themselves throughout a person's lifetime, form all cells of the hematopoietic system.
Medicine/Pharmacology - Computer Science/Telecom
19.07.2017
Smart walk assist improves rehabilitation
A mobile harness suspended from the ceiling is now equipped with intelligent motion analysis for tailored walking rehabilitation in people suffering from spinal cord injury, stroke and other neurological disorders affecting gait.
Computer Science/Telecom - Medicine/Pharmacology
19.07.2017
"It’s always a compromise"
Digitalisation simplifies many aspects of our everyday life, but it also creates new risks. Srdjan Capkun, Professor for Information Security, explains how to find the right balance between convenience and security.
Business/Economics - Medicine/Pharmacology
18.07.2017
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc , -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (U
Medicine/Pharmacology - Life Sciences
17.07.2017
Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche's OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for peop
Medicine/Pharmacology
14.07.2017
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis † Data planned to be presented at a key medical congress in the second half of 2017.
Mechanical Engineering/Mechanics - Medicine/Pharmacology
13.07.2017
Testing a soft artificial heart
Testing a soft artificial heart
ETH researchers from the Functional Materials Laboratory have developed a silicone heart that beats almost like a human heart.
Medicine/Pharmacology - Life Sciences
13.07.2017
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r B
Medicine/Pharmacology - Administration/Government
10.07.2017
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
Positive phase III results for Roche's emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing agents Data from HAVEN 1 in adults and adolescents and inte
Medicine/Pharmacology
06.07.2017
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis , † Update also includes use of Cosentyx in moderate-to-severe scalp ps
Agronomy/Food Science - Medicine/Pharmacology
05.07.2017
Naturalness as a success factor
Naturalness as a success factor
"Naturalness" is a construct - but according to a new study from the ETH Consumer Behavior group, a product's success on the food market is primarily defined by whether or not consumers perceive it as natural. The increasingly artificial and virtual nature of everyday life has now achieved broad acceptance, and the benefits that technological development bring to everyone cannot be denied.
Medicine/Pharmacology - Life Sciences
29.06.2017
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance † Zykadia benefit was also seen in patients
Life Sciences - Medicine/Pharmacology
29.06.2017
Designed Proteins to Treat Muscular Dystrophy
Designed Proteins to Treat Muscular Dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage. Individuals who suffer from muscular dystrophy often lack essential components in this cell scaffold. As a result, their muscles lack strength and become progressively weaker. The research team of Prof. Markus RŁegg at the Biozentrum, University of Basel, has now designed two proteins that stabilize the cell scaffolding link it to the muscle fiber and thereby restore muscle structure and function.
Medicine/Pharmacology - Life Sciences
28.06.2017
The gene behind follicular lymphoma
The gene behind follicular lymphoma
EPFL scientists have discovered an important gene whose loss lies behind follicular lymphoma, an incurable cancer. Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma†develops when the body starts making abnormal B-cells, which are white blood cells that in normal conditions fight infections.
Medicine/Pharmacology - Life Sciences
27.06.2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for heal
Medicine/Pharmacology - Administration/Government
27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of
Medicine/Pharmacology - Life Sciences
26.06.2017
Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting Roche today announced positive data from the p
Medicine/Pharmacology - Life Sciences
23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data † Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months † Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania † CTL019 is manufactured us
Medicine/Pharmacology - Chemistry
23.06.2017
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna and were in TFR at 48 weeks remained in TFR at 96 weeks [1,2] 48-week data from same trials recently added to Tasigna SmPC following EC approval; discussions with other regulatory authorities are underway worldwide - Novartis toda
Medicine/Pharmacology - Life Sciences
23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de
Medicine/Pharmacology - Physics/Materials Science
23.06.2017
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related qualit
Medicine/Pharmacology - Life Sciences
23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U
Medicine/Pharmacology
22.06.2017
ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis † Despite current treatments about 40% of heart attack survivors remain at increased risk of† recurrent heart attack, stroke or cardiovascular death because of hi
Medicine/Pharmacology - Life Sciences
21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o
Medicine/Pharmacology
20.06.2017
Almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 patients , 42% of CU patients studied are not receiving any treatment for their debilitatin
Medicine/Pharmacology
20.06.2017
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III†studies , † 57% and 52% of patients receiving RTH258 6 mg in the respective trials were maintained exclusively on a q12w interval immediately following the loading phase and continuing through week 48 , † In both studies overall ocular and non-ocular adverse event rates for RTH258
Medicine/Pharmacology - Life Sciences
19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
Medicine/Pharmacology
17.06.2017
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease ‚? These new data underscore the disconnect between self-perceived control and clinical reality; a potentially limiting factor in patients seeking support to better control their condition ‚? Helping patients recognize the possibilities of living a life with properly controlled asthma is central to a major new global p
Medicine/Pharmacology - Life Sciences
16.06.2017
Bacteria Free Themselves with Molecular ‘Speargun'
Bacteria Free Themselves with Molecular ‘Speargun’
Many bacteria are armed with nano-spearguns, which they use to combat unwelcome competitors or knockout host cells.
Medicine/Pharmacology
15.06.2017
Novartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx ‚? is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , ‚? Additional data show rapid and sustained pain relief with Cosentyx as early as Week 3 which is sustained out to 2 years in PsA patients ‚? Patient recruitment underway for the new EXCEED head-to-head clinical trial to show superiority of Cosentyx versus Humira ‚? * in PsA The di
Life Sciences - Medicine/Pharmacology
15.06.2017
Gene Transfer Keeps Bacteria Fit
Gene Transfer Keeps Bacteria Fit
Researchers at the University of Basel‚?‘s Biozentrum have discovered that Bartonella bacteria exchange genes efficiently using a domesticated virus encoded in their genome.
Medicine/Pharmacology
15.06.2017
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus‚?
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ‚? Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicin
Medicine/Pharmacology - Life Sciences
13.06.2017
Boost for Zurich biomedicine
Boost for Zurich biomedicine
The Helmut Horten Foundation has supported Zurich's medical hub for many years. Now, a new donation to ETH will enable the strengthening of the Zurich-Ticino ‘health axis'.
Medicine/Pharmacology - Physics/Materials Science
13.06.2017
New "WHO Collaborating Centre for Physical Activity and Health"
A lack of physical activity increases the risk for cardiovascular and respiratory diseases as well as diabetes and cancer.
Life Sciences - Medicine/Pharmacology
12.06.2017
Fighting fire blight and detecting Salmonella
Fighting fire blight and detecting Salmonella
ETH researchers have created an effective weapon against the plant disease fire blight and a new method for detection of Salmonella. Both are based on particular viruses that attack only one species of bacteria. The plant disease fire blight, caused by the bacterium Erwinia amylovora , is dreaded by fruit growers.
Life Sciences - Medicine/Pharmacology
12.06.2017
Uncovering the biology of a painful and disfiguring pediatric disease
Uncovering the biology of a painful and disfiguring pediatric disease
EPFL scientists have identified the biological mechanism behind the painful, potentially lethal, disfiguring Hyaline Fibromatosis Syndrome.‚? Image caption:‚?Loss of ANTXR2 leads to the accumulation of extracellular material in mice uterus and sterility (Left). Collagen 6 removal in mice without ANTXR2 restore uterine structure and function (Right).
1 2 3 4 5 ... 24 Next »

 
 
Logo Careerjet